Ignite Creation Date:
2025-12-24 @ 10:07 PM
Ignite Modification Date:
2026-01-25 @ 8:53 AM
Study NCT ID:
NCT04016935
Status:
TERMINATED
Last Update Posted:
2022-05-17
First Post:
2019-06-26
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
EndoPredict® Extended Endocrine Trial (EXET)
Sponsor:
Myriad Genetic Laboratories, Inc.
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Primary Invasive Breast Cancer | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | ER+ and HER2- Breast Cancer patients | View |
| None | Extended Endocrine Therapy | View |
| None | EndoPredict | View |
| None | Additional Relevant MeSH terms: | View |
| None | Breast Neoplasms | View |
| None | Neoplasms by Site | View |
| None | Neoplasms | View |
| None | Breast Diseases | View |
| None | Skin Diseases | View |